Cabaletta Bio to Participate in Upcoming Investor Conferences in December
Cabaletta Bio (Nasdaq: CABA) has announced its participation in two major investor conferences this December. The company will present a fireside chat at the 7th Annual Evercore HealthCONx Conference on December 4, 2024, at 7:55 a.m. ET in Coral Gables, FL. On the same day, management will be available for one-on-one meetings at Citi's 2024 Global Healthcare Conference in Miami, FL.
The fireside chat will be webcast live and accessible through Cabaletta's website, with replays available for 30 days. The company specializes in developing curative targeted cell therapies for autoimmune diseases.
Cabaletta Bio (Nasdaq: CABA) ha annunciato la sua partecipazione a due importanti conferenze per investitori questo dicembre. L'azienda presenterà una chiacchierata informale durante il 7° Annuale Evercore HealthCONx Conference il 4 dicembre 2024, alle 7:55 a.m. ET a Coral Gables, FL. Nello stesso giorno, il management sarà disponibile per incontri individuali alla 2024 Global Healthcare Conference di Citi a Miami, FL.
La chiacchierata sarà trasmessa in diretta in streaming e sarà accessibile attraverso il sito web di Cabaletta, con la possibilità di rivederla per 30 giorni. L'azienda si specializza nello sviluppo di terapie cellulari curative mirate per malattie autoimmuni.
Cabaletta Bio (Nasdaq: CABA) ha anunciado su participación en dos importantes conferencias de inversores este diciembre. La compañía presentará una charla informal en la 7ª Conferencia Anual Evercore HealthCONx el 4 de diciembre de 2024, a las 7:55 a.m. ET en Coral Gables, FL. Ese mismo día, la dirección estará disponible para reuniones individuales en la Conferencia Global de Salud 2024 de Citi en Miami, FL.
La charla se transmitirá en vivo y estará disponible a través del sitio web de Cabaletta, con repeticiones disponibles durante 30 días. La compañía se especializa en el desarrollo de terapias celulares curativas dirigidas para enfermedades autoinmunes.
카발레타 바이오 (Nasdaq: CABA)가 이번 12월에 두 개의 주요 투자자 회의에 참석한다고 발표했습니다. 이 회사는 2024년 12월 4일 오전 7시 55분 ET에 플로리다주 코랄 게이블스에서 열리는 제7회 에버코어 헬스CONx 컨퍼런스에서 대담을 진행할 예정입니다. 같은 날, 경영진은 플로리다주 마이애미에서 열리는 2024년 시티 글로벌 헬스케어 컨퍼런스에서 일대일 미팅을 진행할 것입니다.
대담은 실시간으로 웹 캐스트되며 카발레타 웹사이트를 통해 접근할 수 있고, 30일간 재생 가능하도록 제공됩니다. 이 회사는 자가면역 질환을 위한 치유형 표적 세포 요법을 개발하는 데 전문화되어 있습니다.
Cabaletta Bio (Nasdaq: CABA) a annoncé sa participation à deux grandes conférences pour investisseurs ce décembre. L'entreprise présentera une discussion informelle lors de la 7ème Conférence Annuelle Evercore HealthCONx le 4 décembre 2024, à 7h55 ET à Coral Gables, FL. Le même jour, la direction sera disponible pour des réunions individuelles à la Conférence Mondiale sur la Santé 2024 de Citi à Miami, FL.
La discussion sera diffusée en direct et accessible via le site Web de Cabaletta, avec des rediffusions disponibles pendant 30 jours. L'entreprise se spécialise dans le développement de thérapies cellulaires curatives ciblées pour les maladies auto-immunes.
Cabaletta Bio (Nasdaq: CABA) hat seine Teilnahme an zwei großen Investorenkonferenzen im Dezember bekannt gegeben. Das Unternehmen wird am 4. Dezember 2024 um 7:55 Uhr ET einen informellen Austausch auf der 7. jährlichen Evercore HealthCONx-Konferenz in Coral Gables, FL, präsentieren. Am selben Tag wird das Management für persönliche Gespräche auf der 2024 Global Healthcare Conference von Citi in Miami, FL, zur Verfügung stehen.
Der Austausch wird live im Internet übertragen und ist über die Website von Cabaletta zugänglich, wobei Wiederholungen für 30 Tage verfügbar sind. Das Unternehmen ist auf die Entwicklung heilender, zielgerichteter Zelltherapien für Autoimmunerkrankungen spezialisiert.
- None.
- None.
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following investor conferences in December:
- 7th Annual Evercore HealthCONx Conference: Fireside chat on Wednesday, December 4, 2024, at 7:55 a.m. ET in Coral Gables, FL. Members of management will also be available for one-on-one meetings.
- Citi’s 2024 Global Healthcare Conference: Members of management will be available for one-on-one meetings on Wednesday, December 4, 2024, in Miami, FL.
A live webcast of the fireside chat will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. CABA-201 is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit www.cabalettabio.com and connect with us on LinkedIn.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
William Gramig
Precision AQ
william.gramig@precisionaq.com
FAQ
When is Cabaletta Bio (CABA) presenting at the Evercore HealthCONx Conference?
Which investor conferences is Cabaletta Bio (CABA) attending in December 2024?
Where can investors watch Cabaletta Bio's (CABA) December 2024 fireside chat?
